A new council will oversee the safety of vaccines and other products on the market, the Food and Drug Administration said on Nov. 19. The Center for Biologics Evaluation and Research (CBER) regulates products such as vaccines and gene therapies. The new CBER Safety Council will oversee product safety. “By bringing together senior scientific and regulatory experts from across the center, the new council provides a layer of review that is distinct from the product offices that conduct premarket approval, ensuring that safety assessments that support post-marketing actions are comprehensive and consistent, and the scientific evidence behind FDA’s decisions is transparently communicated to the public,” the FDA said in a statement. The council will review safety signals in CBER-regulated products; conduct risk-benefit assessments for potential regulatory action; recommend regulatory action, including product withdrawal, to the FDA; publish public-facing safety communications; and coordinate with partners such as the Centers for Disease Control and Prevention. The council will utilize data from surveillance systems run by the FDA and CDC, including the Vaccine Adverse Event Reporting System (VAERS). Health Secretary Robert F. Kennedy Jr. has said the existing systems are deficient and that officials are overhauling them. The council will be within the center but separate from the CBER product offices. An individual in the position of senior adviser for postmarketing safety will manage the council and report directly to the CBER director, former Merck official Karim Mikhail. The manager’s name and the council members have not been released.